NCT01653093

Brief Summary

In standard clinical care, the prostate is imaged by magnetic resonance imaging (MRI) which is a procedure to take pictures of body structures by using a strong magnetic field and radio waves. The strength of the magnet used is expressed in the unit Tesla (T); a higher Tesla number means the magnet has stronger pull. Standard magnetic resonance imaging of the prostate uses a magnet 1.5 Tesla strong as well as a specialized endorectal coil (antenna) inserted into the body due to the limitations using an external body coil at this magnet strength. MRI using a 3 Tesla magnet has a theoretical advantage over imaging at 1.5 Tesla of creating a signal twice as strong that can be received by the antennas, resulting in better pictures. The goal of this study is to make the MRI procedure more comfortable for patients by using an external coil instead of an endorectal coil. With this study, researchers also want to help patients' health care teams, the surgeons in particular. Researchers will assess the impact of prostate MRI, without an endorectal coil, done at 3 Tesla and with an external body coil on helping doctors decide which approaches to disease therapy might be best for patients as well as correlate patients' study images with all other clinical imaging

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
280

participants targeted

Target at P75+ for not_applicable prostate-cancer

Timeline
8mo left

Started Sep 2007

Longer than P75 for not_applicable prostate-cancer

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress97%
Sep 2007Dec 2026

Study Start

First participant enrolled

September 20, 2007

Completed
4.9 years until next milestone

First Submitted

Initial submission to the registry

July 26, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 30, 2012

Completed
14.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

April 11, 2025

Status Verified

April 1, 2025

Enrollment Period

19.3 years

First QC Date

July 26, 2012

Last Update Submit

April 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Diagnostic imaging quality of the prostate at 3T high field imaging without an endorectal coil

    The primary outcome in this study is the agreement in tumor staging between pathology and 3 Tesla MRI.

    Up to 6 years

Study Arms (1)

Diagnostic (3T MRI)

EXPERIMENTAL

Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.

Procedure: 3-Tesla magnetic resonance imaging (3T MRI)Procedure: diffusion-weighted magnetic resonance imagingProcedure: dynamic contrast-enhanced magnetic resonance imagingProcedure: magnetic resonance spectroscopic imaging

Interventions

Undergo 3T MRI

Also known as: 3-Tesla MRI, 3T MRI
Diagnostic (3T MRI)

Undergo diffusion-weighted MRI

Also known as: diffusion-weighted MRI
Diagnostic (3T MRI)

Undergo DCE-MRI

Also known as: DCE-MRI
Diagnostic (3T MRI)

Undergo MR spectroscopy

Also known as: 1H-nuclear magnetic resonance spectroscopic imaging, Proton Magnetic Resonance Spectroscopic Imaging
Diagnostic (3T MRI)

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with known or suspected prostate disease based on clinical data will be included in the study; patients with intermediate to high grade prostate cancer (Gleason's score \>= 7 and prostate-specific antigen \[PSA\] of \> 10ng/dl) will be referred from the outpatient clinics after evaluation by the treating physicians
  • Written informed consent will be signed by the patients before the MRI based on the guidelines approved by the Ohio State University Institutional Review board
  • Patients must have an estimated glomerular filtration rate of \>= 30 mL/min/1.73m\^2 within six weeks of the MRI to be included in the study

You may not qualify if:

  • Patients with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.)
  • Patients with any type of ferromagnetic bioimplant that could potentially be displaced or damaged
  • Patients that have vascular or aneurysm clips, or metallic staples from a surgical procedure
  • Patients with permanent tattoo eye liner (may contain metallic coloring)
  • Patients that may have shrapnel imbedded in their bodies, such as from war wounds, metal workers and machinists (metallic fragments in or near eyes), severe auto accident victims
  • Patients that exhibit noticeable anxiety and/or claustrophobia
  • Patients who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher
  • Patients who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function)
  • Patients with an estimated glomerular filtration rate of \< 30 mL/min/1.73m\^2 within six weeks of the MRI
  • Acute or chronic severe renal insufficiency (estimated glomerular filtration rate \< 30 mL/min/1.73m\^2)
  • Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Ohio State University Medical Center, Stress

Columbus, Ohio, 43210, United States

Location

Related Links

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Michael Knopp, MD

    Ohio State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 26, 2012

First Posted

July 30, 2012

Study Start

September 20, 2007

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

April 11, 2025

Record last verified: 2025-04

Locations